Abstract: Insulin preparations of superior physical stability, comprising dissolved and/or precipitated human insulin or an analogue or derivative thereof, and a water-soluble reduced or non-reducing carbohydrate containing at least 4 carbon atoms in the main carbohydrate structure, or a water-soluble non-reducing ester and/or ether derivative of a carbohydrate or reduced carbohydrate containing at least 4 carbon atoms in the main carbohydrate structure, or mixtures thereof are disclosed.

Abstract: A glycoside represented by formula (I), wherein dexamethasone or betamethasone is the aglycon and the 21-position is substituted by a simple sugar or an acylated sugar selected from the group consisting of glucose, galactose, mannose, rhamnose, fucose, N-acetylglucosamine, N-acetylgalactosamine, galacturonic acid, glucuronic acid and sialic acid.

Abstract: A salicylic acid (SA) and derivitized beta cyclodextrin complex provides that the SA display increased solubility in water. The complex includes about 0.1 to about 10.0 percent salicylic acid, about 0.1 to about 75.0 percent derivatized beta cyclodextrin and about 0.1 to about 50.0 percent water.

Abstract: The process for activating polysaccharides consists of contacting the polysaccharide with liquid ammonia at an initial pressure which is higher than atmospheric pressure and at a temperature of at least approximately 25.degree. C., the amount of liquid ammonia being sufficient at least for wetting the surface of the polysaccharide starting material which is then expanded. The volume available for the polysaccharide/liquid ammonia system is enlarged in the manner of an explosion by lowering the pressure by at least 5 bar. The process is particularly suitable for activating cellulose, guar gum, starch and chitin. The process enables cellulose to be modified in a novel manner. The activated polysaccharides display higher reactivity and improved elimination of reagents during acylation, alkylation, silylation, xanthogenation and carbomoylation with largely homogeneous reaction processes.

Abstract: A keratan sulfate oligosaccharide which comprises from two to five sugar units and has sulfated N-acetylglucosamine at the reducing end and in a molecule of which at least two hydroxyl groups are sulfated, preferably, which contains at least disaccharide represented by the formula Gal(6S)-GlcNAc(6S) (in the formula, Gal, GlcN, Ac, and 6S represent a galactose, a glucosamine, an acetyl group, and a 6-O-sulfate ester, respectively) as a constitutional ingredient, and/or pharmaceutically acceptable salt thereof are used as active ingredients of anti-inflammatory agents, antiallergic agents, immunomodulators, cell differentiation inducers, and apoptosis inducers.

Abstract: Polyionic derivatives of cyclodextrins and methods for preparing these derivatives are provided in which a polyionic derivative of cyclodextrin is combined with a growth factor, preferably a heparin binding growth factor. These compositions are of low solubility and are applied directly to the location of a wound. By virtue of the low solubility, the compositions remain in place at the site of application and slowly release growth factor. In an alternative embodiment, the cyclodextrin derivatives are administered in the absence of growth factor and are used to absorb growth factor present in the body at the location of the wound in order to prevent overstimulation of the wound response.

Abstract: The present invention is directed to deacyl teicoplanin, and to a process for preparing deacyl teicoplanin by reacting teicoplanin with ECB deacylase. Deacyl teicoplanin can be alkylated to produce compounds useful for their antibacterial activity.

Abstract: The present invention provides illudin analogs of the general formula (I): ##STR1## where R.sub.1 is (CH.sub.2).sub.n --X--Y or H; n is 0 to 4; X is O or S or N or absent; and Y is an optionally substituted (C.sub.1 -C.sub.8)alkyl, (C.sub.6 -C.sub.10)aryl, (C.sub.6 -C.sub.10)aryl(C.sub.1 -C.sub.4)alkyl or cyclo(C.sub.3 -C.sub.6)alkyl optionally comprising one or more heteroatoms; a monosaccharide, an amino acid residue, or H when n is 2-4; R.sub.2 is absent; or R.sub.1 and R.sub.2 together comprise a 5-7 membered cyclic ring;R.sub.3 is (C.sub.1 -C.sub.4)alkyl or H; R.sub.4 is H, SCH.sub.2 CO.sub.2 (C.sub.1 -C.sub.4)alkyl, O--(C.sub.5 --C.sub.12)aryl or --S--(C.sub.5 -C.sub.12)aryl; R.sub.5 is H, OH or absent; R.sub.6 is (C.sub.1 -C.sub.4)alkyl or absent; R.sub.7 is OH or OSi((C.sub.1 -C.sub.4)alkyl).sub.3 ; orR.sub.6 and R.sub.7 together are ethylenedioxy;R.sub.8 is optionally substituted (C.sub.1 -C.sub.4)alkyl; andthe bonds represented by -- are individually present or absent.

Abstract: Pectins from gel and rind cell wall fibers of Aloe vera are extracted, isolated and identified. Two classes of Aloe pectin are obtained: the high-molecular-weight (HMW) pectin and the low-molecular-weight (LMW) pectin. Aloe pectins have a low methoxyl (LM) content. Aloe pectins form gel in the presence of calcium, and they, especially, the HMW pectin, form monovalent cation-based gels at low temperature, which revert back to solution when brought to room temperature. The HMW Aloe pectin-calcium gel is used for controlled release. The monovalent cation-based gel is used as a matrix for storing pharmacological substances and also for antigen and antibody precipitation reaction.

Abstract: The present invention relates to a process for preparing cellulose esters having a total DS/AGU of 0.1 to 3.0, said process consisting of contacting the following:(i) a cellulose material,(ii) a solubilizing amount of a solvent system comprising a carboxamide diluent or a urea-based diluent,(iii) an acylating reagent, and(iv) a titanium-containing compound.

Abstract: An aryl glucuronide of 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide, preferably an O-aryl glucuronide, as well as methods for the convenient synthesis of these aryl glucuronides, highly stable and low toxicity pharmaceutical composition containing these aryl glucuronides, and methods for use of these pharmaceutical compositions, for example, for treatment of inflammation, infections, etc.

Abstract: Accordingly, a method is provided for concentrating precursors to vertebrate connective tissue in foodstuffs to be ingested by humans and pets as part of their daily sustenance. The present method comprises the following steps: (a) providing raw vertebrate connective tissue; (b) disintegrating the raw vertebrate connective tissue into an aggregation of particles having a substantially homogenous particle size, preferably via an emulsification process, thereby forming liquefied connective tissue; and (c) thermally processing the liquefied connective tissue, resulting in a readily-edible foodstuff rich in chondroitin sulfates, glucosamine, and other connective tissue building blocks.

Abstract: Cellulose acetate having a high moldability and low solution viscosity in spite of having a high average degree of polymerization is obtained. The low molecular weight components of cellulose acetate (e.g., CTA having average degree of acetylation of 59.0 to 62.5%) are eluted with a washing solvent to produce a cellulose acetate having a molecular weight distribution Mw/Mn of 1 to 1.7. As the washing solvent, those swell or partially dissolve the cellulose acetate, for example, those which dissolve 0.1 to 30% by weight of cellulose acetate can be used. This solvent includes, for example, a solvent having a solubility parameter .delta. of 7 to 12.5 (ketones, ethers, organic acid, esters, etc.).

Abstract: Methods for recovering isoflavones and derivatives thereof from soy molasses are disclosed. In a first embodiment, a method is disclosed in which isoflavones are recovered without any significant conversion of isoflavone conjugates to other forms. In a second embodiment, a method is disclosed whereby isoflavone conjugates are converted to glucosides while in the soy material prior to their recovery. In a third embodiment, a method is disclosed in which isoflavones are converted to their aglucone form while in the soy material and prior to their recovery. Also disclosed are various isoflavone enriched products obtained from soy molasses.

Abstract: The present invention is directed to N.sup.LEU -carbamoyl and thiocarbamoyl derivatives of A82846B and N.sup.DISACC variations thereof. These derivatives are useful as antibacterials and also as starting materials from which further antibacterial compounds are prepared.

Abstract: The present invention provides antimicrobial skin-preparations useable to disinfect a surgical site for surgery. The antimicrobial skin-preparation formula includes iodine, alcohol and gel. The new pre-operative skin-preparation quickly and effectively kills microorganisms when applied to the surgical site. The skin-preparation continues to effectively inhibit microorganism growth in the applied area over an extended period of time. One gel skin-preparation according to the invention includes alcohol at 60%-90% v/v, iodine at 1.0%-15.0% w/v, and gel at 0.1%-30.0% w/v. A carrier solvent and other optional components may also be added to the formula.

Abstract: A non- or substantially non-crystalline high trehalose content syrup, which dissolves trehalose in an amount over the water solubility and dissolves other oligosaccharide having a trehalose structure within the molecule. The oligosaccharide acts as a trehalose crystallization inhibitory agent and makes the syrup stable, free of or substantially free of crystallization at ambient temperature, and free from bacterial contamination. Examples of the oligosaccharide are monoglucosyltrehalose, diglucosyltrehalose, and triglucosyltrehalose.

Abstract: An object of the invention is to obtain cellulose acetate having improved physical properties, particularly film strength and improved flexibility of the molded product. Cellulose acetate having an average degree of acetylation of not less than 59%, viscosity average degree of polymerization (DP) of not less than 290. and concentrated solution viscosity (.eta.) according to falling ball viscosity method for viscosity average degree of polymerization (DP) expressed by the following formula (1):2.814.times.ln(DP)-11.753.ltoreq.ln(.eta.).ltoreq.7.28.times.ln(DP)-37.059( 1)and a process for the production thereof.

Abstract: Composition for the treatment or prevention of the symptoms of connective tissue ageing, characterized in that it contains one or more oligosaccharides with 2 to 5 oligosaccharide residues or a derivative of said oligosaccharide(s) containing a hydrophobic residue, with the proviso that one galactose residue be present in a non-reducing terminal position of said oligosaccharide(s).

Abstract: Disclosed are novel synthetic processes for the preparation of the trisaccharide .alpha.Gal(1.fwdarw.4).beta.Gal(1.fwdarw.4)Glc-OR compounds.